|MDACC Study No:||2012-0086 (clinicaltrials.gov NCT No: NCT01752426)|
|Title:||A Pilot Study to determine the effects of the Bruton’s tyrosine kinase (Btk)|
inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using Heavy Water
Labeling in subjects with Chronic Lymphocytic Leukemia (CLL) and Small
Lymphocytic Lymphoma (SLL).
|Principal Investigator:||Jan A. Burger|
|Treatment Agent:||Heavy Water; PCI-32765|
|Study Description:||The goal of this clinical research study is to learn how PCI-32765 (ibrutinib) |
may affect the life cycle of blood-cancer cells. Cancer cells will be "labeled"
with heavy water to learn about their birth rates and death rates.
Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins
inside cells that help cells live and grow. The study drug is designed to
inhibit or "block" the activity of a type of kinase that helps blood-cancer
cells live and grow. By blocking the activity of this specific kinase, it is
possible that the study drug may kill the cancer cells or stop them from
Heavy water (2H2O) is a special type of water that is designed to help
researchers learn how quickly cancer cells in the body reproduce.